Form 4: Neurocrine Biosciences Chief Regulatory Officer Executes Stock Option and Sells Shares Under 10b5-1 Plan

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares of common stock on December 17, 2024, according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On December 17, 2024, Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised 1,091 stock options at a price of $79.02 per share.
• Simultaneously, Delaet sold 1,091 shares of Neurocrine Biosciences common stock at $135 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 2,507 shares of common stock and 2,990 non-qualified stock options.
• The stock options were granted on January 31, 2022, vest monthly over 48 months starting February 28, 2022, and expire on January 31, 2032.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of insider trading activity under a pre-existing plan. It doesn't inherently signal positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to utilize Rule 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates